AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 119_CD 32_CD Statutory_NNP and_CC other_JJ information_NN 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Audit_NNP fees_NNS KPMG_NNP Audit_NNP Plc_NNP and_CC its_PRP$ associates_NNS Audit_NNP services_NNS 8.4_CD 5.4_CD 3.5_CD Further_JJ assurance_NN services_NNS 1.4_CD 2.1_CD 1.5_CD Taxation_NNP services_NNS 2.0_CD 1.8_CD 1.8_CD Other_JJ services_NNS 0.2_CD 11.8_CD 9.3_CD 7.0_CD Audit_NNP fees_NNS others_NNS 0.1_CD 11.8_CD 9.3_CD 7.1_CD Audit_NNP services_NNS include_VBP fees_NNS in_IN respect_NN of_IN the_DT Group_NNP audit_NN ,_, the_DT audit_NN of_IN the_DT Groups_NNS preliminary_JJ financial_JJ statements_NNS under_IN International_NNP Financial_NNP Reporting_NNP Standards_NNP ,_, work_NN in_IN relation_NN to_TO Sarbanes-Oxley_NNP s404_CD ,_, and_CC fees_NNS for_IN other_JJ services_NNS required_VBN by_IN statute_NN or_CC regulation_NN ._.
Fees_NNS for_IN further_JJ assurance_NN services_NNS include_VBP employee_NN pension_NN fund_NN and_CC other_JJ benefit_NN plan_NN audit_NN services_NNS together_RB with_IN control_NN reviews_NNS associated_VBN with_IN new_JJ systems_NNS implementations_NNS ._.
Taxation_NNP services_NNS consist_VBP of_IN tax_NN compliance_NN services_NNS and_CC tax_NN advice_NN ._.
$_$ 0.9_CD m_NN 2003_CD $_$ 0.5_CD m_NN ,_, 2002_CD $_$ 0.4_CD m_NN of_IN the_DT total_NN fees_NNS for_IN further_JJ assurance_NN ,_, taxation_NN and_CC other_JJ services_NNS were_VBD charged_VBN in_IN the_DT UK_NNP ._.
Related_VBN party_NN transactions_NNS The_DT Group_NNP had_VBD no_DT material_NN related_VBN party_NN transactions_NNS which_WDT might_MD reasonably_RB be_VB expected_VBN to_TO influence_VB decisions_NNS made_VBN by_IN the_DT users_NNS of_IN these_DT Financial_NNP Statements_NNP ._.
Subsequent_JJ events_NNS No_DT significant_JJ change_NN has_VBZ occurred_VBN since_IN the_DT date_NN of_IN the_DT annual_JJ Financial_NNP Statements_NNP ._.
